La. Woman Says Ozempic, Mounjaro Makers Failed to Warn of Severe Gastrointestinal Events

LAKE CHARLES, La. — A Louisiana woman has sued Novo Nordisk and Eli Lilly & Co., accusing them of failing to warn that their injectable type 2 diabetes drugs Ozempic and Mounjaro can cause paralyzed stomach or inflammation of the stomach and intestines.

In an Aug. 2 complaint filed in the U.S. District Court for the Western District of Louisiana, Jacklyn Bjorklund says defendants “have downplayed the severity of the gastrointestinal events” caused by the GLP-1 receptor drugs and that they carry a risk of gastroparesis or gastroenteritis.

Gastroparesis affects normal muscle movement in the stomach, hampering its ability …